It has been conjugated to mAbs targeting PSMA, HER2, mesothelin, and CD22 by means of a bifunctional chelator such as octadentate 3,2-hydroxypyridinone (3,2-HOPO) and was shown to have therapeutic efficacy in various pre-clinical tumor models [101]. Here, ERBB2 is linked to neoplasm.